Dr Peter Hamley
“I'm thrilled to be a part of the UKI2S board, contributing to the vital work of the UK Innovation and Science Fund. This fund plays a pivotal role in fostering growth within the UK’s life sciences, biotech, and pharma sectors for the benefit of our economy and nation. I am excited about the prospect of integrating innovative technologies into the public sector and am honoured to embark on this journey with UKI2S. Supporting both UKI2S and the portfolio companies they champion is a gratifying opportunity to contribute to the development and launch of new and innovative technologies.”

Dr Peter Hamley

Dr Peter Hamley is an Advisory Board Member for UKI2S. Peter has a long history in the BioTech Industry, having started his career at AstraZeneca after graduating from his postdoctoral studies at the University of Pennsylvania and his PhD from Cambridge University. He also obtained his MBA from the University of Bath.

Having spent over a decade at Sanofi, aiding in global drug discovery across leadership and development roles – Peter’s experience is unparalleled, pushing advancements across many therapeutic areas throughout his time in the organisation.

Currently, Peter is CSO of Samsara Therapeutics, leading the biotech industry in autophagy therapeutics – vital in helping prevent disease caused by neurodegeneration.

His unique blend of expertise has resulted in a fantastic repertoire of more than 60 patents, papers and book chapters published under his name.

Peter’s wealth of knowledge and experience is a vibrant asset to UKI2S, enabling enhanced decision making during investment into life-changing organisations within the biotech and life sciences sectors.

UK Innovation & Science Seed Fund Team